RxDoctor Payments Data

Shaun Ajinkya, MD

Neurology · Rochester, MNNPI 1952750416

Payments from drug & device makers

$3,620in general payments, 2019–2025

Across 160 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$540
  • EMD Serono, Inc.$380
  • AbbVie$315
  • Novartis$200
  • Neurelis, Inc.$169
  • Biogen$146
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$3,47696%
  • Education$1444%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,620 in reported general payments places this provider in the 70th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$49,638
Medicare patients
401
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$320,295
BriviactBrivaracetam39$87,912
Nurtec OdtRimegepant Sulfate74$86,702
Aimovig AutoinjectorErenumab-Aooe74$62,811
Dimethyl Fumarate11$48,609
UbrelvyUbrogepant28$43,049
FycompaPerampanel27$35,140
Oxtellar XrOxcarbazepine22$34,535
Lacosamide212$25,220
AptiomEslicarbazepine Acetate16$23,619
XcopriCenobamate17$22,603
VimpatLacosamide13$19,589
EliquisApixaban23$19,560
Ajovy AutoinjectorFremanezumab-Vfrm15$17,575
QuliptaAtogepant13$14,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$49$320,29512 claims
PfizerNurtec Odt, Eliquis, Dilantin$70$110,686116 claims
UCB, Inc.Briviact, Vimpat$540$107,50252 claims
AbbVieUbrelvy, Qulipta$315$57,91741 claims
Eisai Inc.Fycompa$14$35,14027 claims
Sunovion Pharmaceuticals Inc.Aptiom$15$23,61916 claims
SK Life Science, Inc.Xcopri$65$22,60317 claims
Neurelis, Inc.Valtoco$169$14,37518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 434 neurology providers in Minnesota.

Other neurology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →